Checkpoint Inhibitor Therapy

WASHINGTON — Preexisting autoimmune diseases do not increase mortality risk in patients treated with immune checkpoint inhibitors for cancer, according to data presented at ACR Convergence 2024.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights current challenges within the EGFR-mutated lung cancer space.

Patients with cancer who received immune checkpoint inhibitors exhibited increased risk for psoriasis compared with those treated with chemotherapy or targeted therapy.

The addition of immune checkpoint inhibitor therapy to neoadjuvant chemotherapy improved pathologic complete response and EFS for certain patients with early-stage breast cancer, according to a systematic review and meta-analysis.

Certain individuals with non-cell lung cancer who experienced immune-related adverse events due to immune checkpoint inhibitor therapy had improved survival outcomes, according to retrospective study data published in JAMA Network Open.

Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

Indications for the use of checkpoint inhibitors are ever expanding. However, even as these drugs have helped patients with cancer live longer, the emergence of various immune related adverse events limits their full potential in many.

The cutaneous toxicities associated with cancer checkpoint inhibitors were varied depending on the malignancy and checkpoint inhibitor used, according to a study.